Muscular Atrophy Market Insights and Market Analysis

1. Spinal Muscular Atrophy Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight The Spinal Muscular Atrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Spinal Muscular Atrophy market dynamics. DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Spinal Muscular Atrophy Market Report:

2. ● The Spinal Muscular Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032) According to the National Organization for Rare Disorders (NORD), the prevalence of all types of Spinal Muscular Atrophy (SMA) has been estimated to be 4-7.8 per 100,000 live births An estimated 80% of Spinal Muscular Atrophy (SMA) patients have the Werdnig-Hoffmann form i.e. Type 1 SMA. It further stated that the condition is diagnosed in only 150 to 200 people Key Spinal Muscular Atrophy Companies: Biogen, Novartis, Genentech, Inc., Hoffmann-La Roche, Astellas Pharma Global Development, and others Key Spinal Muscular Atrophy Therapies: Olesoxime, GYM329, Nusinersen, Itraconazole, Reldesemtiv, and others The Spinal Muscular Atrophy epidemiology based on gender analysis shows it can be concluded that Spinal Muscular Atrophy (SMA) occurs equally in men and women ● ● ● ● ● Request a sample for the Spinal Muscular Atrophy Market Report Spinal Muscular Atrophy Overview Spinal muscular atrophy (SMA) is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. SMA is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of SMA is known as ‘5q SMA’ due to its genetic cause. SMA follows the autosomal mode of inheritance and its onset ranges from infants to adolescence. Human chromosome 5 has two identical genes SMN1 and SMN2. SMN1 encodes 100% fully functional SMN protein, whereas SMN2 encodes only10-20% of functional SMN protein. Mutation of SMN1 is the main reason for this disorder and the severity of the disease depends on the number of SMN2 gene copies. The healthy person carries 2 copies of the SMN2 gene, but in SMA-affected patients it can vary from 1 to 4. Greater the number of SMN2 gene copies, the milder the effect of the disorder. The other SMAs form a genetically very heterogeneous group of rare disorders, differing in their mode of inheritance, the topography of the muscular deficit, and the association with other neurological abnormalities. Spinal Muscular Atrophy Symptoms The Spinal Muscular Atrophy symptoms include – ● ● ● ● ● ● Floppy or weak arms and legs Movement problems Twitching or shaking muscles None and joint problems Swallowing problems Breathing difficulties Discover more about therapies set to grab major Spinal Muscular Atrophy market share @ Spinal Muscular Atrophy market forecast Spinal Muscular Atrophy Epidemiology Segmentation: The Spinal Muscular Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

3. ● ● ● ● Total Prevalence of Spinal Muscular Atrophy Prevalent Cases of Spinal Muscular Atrophy by severity Gender-specific Prevalence of Spinal Muscular Atrophy Diagnosed Cases of Episodic and Chronic Spinal Muscular Atrophy Spinal Muscular Atrophy Market The dynamics of the Spinal Muscular Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Risdiplam, Nusinersen, and others during the forecasted period 2019-2032. Download the report to understand which factors are driving Spinal Muscular Atrophy epidemiology trends @ Spinal Muscular Atrophy Epidemiological Insights Spinal Muscular Atrophy Market Drivers ● ● ● Newborn Screening for SMA Promising Upcoming Launches and Approval Raising Awareness for SMA Spinal Muscular Atrophy Therapies ● ● ● ● ● Olesoxime GYM329 Nusinersen Itraconazole Reldesemtiv Spinal Muscular Atrophy Key Companies ● ● ● ● ● Biogen Novartis Genentech, Inc. Hoffmann-La Roche Astellas Pharma Global Development Scope of the Spinal Muscular Atrophy Market Report ● ● Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Spinal Muscular Atrophy Companies: Biogen, Novartis, Genentech, Inc., Hoffmann-La Roche, Astellas Pharma Global Development, and others Key Spinal Muscular Atrophy Therapies: Olesoxime, GYM329, Nusinersen, Itraconazole, Reldesemtiv, and others Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies Migraine Market Dynamics: Spinal Muscular Atrophy market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies ● ● ● ● ●

4. ● Unmet Needs, KOL’s views, Analyst’s views, Spinal Muscular Atrophy Market Access and Reimbursement Spinal Muscular Atrophy Market Barriers ● ● High-treatment Cost Competition for Emerging Therapies To know more about Spinal Muscular Atrophy treatment, visit @ Spinal Muscular Atrophy Medications Related Reports: Spinal Muscular Atrophy Pipeline "Spinal Muscular Atrophy Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Spinal Muscular Atrophy market. A detailed picture of the Spinal Muscular Atrophy pipeline landscape is provided, which includes the disease overview and Spinal Muscular Atrophy treatment guidelines. Spinal Muscular Atrophy Epidemiology DelveInsight's 'Spinal Muscular Atrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Spinal Muscular Atrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight

5. DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services